Alnylam Pharmaceuticals vs BioMarin Pharmaceutical
ALNY and BMRN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ALNY and BMRN compare
Alnylam Pharmaceuticals is the larger company, worth 1.9 times as much as BioMarin Pharmaceutical ($22.1B against $11.3B).
BioMarin Pharmaceutical scores higher on the StockData Score (8 against 7 for Alnylam Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ALNY | BMRN |
|---|---|---|
| Size and price | ||
| Market cap | $22.1B | $11.3B |
| Share price | $165.00 | $58.51 |
| Change, 1 year | −65.7% | 12.8% |
| Change, 5 years | −11.9% | −30.3% |
| Beta (5Y) | 0.88 | 0.59 |
| Employees | 2,500 | 3,221 |
| StockData Score | ||
| Total score | 7 | 8 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 1 | 3 (better) |
| Performance score | 1 | 2 (better) |
| Health score | 5 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 154× |
| P/S | – | 3.3× |
| P/B | 6.1× | 1.8× (better) |
| EV/EBITDA | – | 48.4× |
| P/FCF | – | 15.3× |
| PEG | – | 4.54 |
| FCF yield | – | 6.5% |
| Fair value | – | $23.86 |
| Margin of safety | – | −145% |
| Growth | ||
| Revenue growth (TTM) | – | 11.2% |
| Revenue growth, 5Y average | 49.8% (better) | 11.6% |
| Net income growth (TTM) | 2137% (better) | −88.9% |
| EPS growth (TTM) | – | −88.7% |
| EPS growth, 5Y average | – | −16.7% |
| Profitability | ||
| Gross margin | – | 76.1% |
| Operating margin | – | 4.4% |
| Net margin | – | 2.1% |
| FCF margin | – | 21.7% |
| Return on equity | 127% (better) | 1.2% |
| Return on invested capital | – | 1.0% |
| Financial health | ||
| Debt / equity | 0.00 | 0.66 (better) |
| Net debt / EBITDA | – | 10.96 |
| Interest coverage | – | 2.0× |
| Current ratio | 2.48 (better) | 2.39 |
| Altman Z-score | 2.75 (better) | 1.86 |
| Piotroski F-score | 6 (better) | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 99.8% | 101% |
| Held by insiders | 0.49% | 0.53% |
| Insider net buying, 12 months | −$43.6M | −$4.3M (better) |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 5.8% | 6.0% |
Go deeper
- ALNY stock overview
- ALNY income statement
- ALNY valuation and score
- BMRN stock overview
- BMRN income statement
- BMRN valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.